Pharma firm Assertio Q3 adjusted EPS beats estimates on strong Rolvedon sales

Assertio Holdings

10/11/2025 21:24

Overview

Assertio Q3 adjusted EPS beats analyst expectations, driven by Rolvedon sales

Adjusted EBITDA for Q3 beats consensus, reflecting strong operational performance

Company narrows FY2025 sales and EBITDA guidance

Outlook

Assertio narrows FY2025 net product sales guidance to $110-112 mln

Company updates FY2025 adjusted EBITDA guidance to $14-16 mln

Assertio cites Rolvedon pull-forward for updated 2025 guidance

Result Drivers

ROLVEDON SALES - Rolvedon net product sales increased significantly to $38.6 mln, driven by both normal demand and large distributor purchases for future supply

INTEGRATION EFFORTS - Co advanced integration efforts to consolidate operations under Assertio Specialty Pharmaceuticals, aiming for greater efficiency and cost savings

INDOCIN SALES DECLINE - Indocin sales fell to $4.8 mln due to expected impacts from generic competition

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Adjusted EPS
Beat
$0.18
-$0.09 (4 Analysts)
Q3 EPS
$0.11
Q3 Net Income
$11.40 mln
Q3 Adjusted EBITDA
Beat
$20.90 mln
$3.70 mln (3 Analysts)
Q3 Income From Operations
$11.48 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Assertio Holdings Inc is $3.00, about 74.7% above its November 7 closing price of $0.76

Press Release: ID:nBwWBCr4a

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)